| |
VA researchers develop biomed innovations in all areas of healthcare, from substance abuse treatments to visual impairment aids and more. License and commercialize VA innovations with no-cost help from TechLink. Learn about available technologies. 
|
|
Today’s Big NewsJul 22, 2024 |
| By Nick Paul Taylor Innovent has pulled off another late-phase win for its Eli Lilly-partnered GLP-1 drug candidate, linking the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China. |
|
|
|
By Annalee Armstrong Allarity Therapeutics has received notice from the Securities and Exchange Commission that an enforcement action is pending regarding FDA meetings surrounding the new drug application for cancer therapy dovitinib. |
By James Waldron Actuate Therapeutics was already keeping its planned IPO on the modest side, but the cancer-focused biotech has now lowered those expectations even further. |
Sponsored by CSafe Global How is the cold chain adapting to the cell and gene therapy boom? Emilio Frattaruolo, Vice President of Cell and Gene Therapies at CSafe, discusses the logistical challenges and innovations shaping the future of these revolutionary treatments. |
|
Cryoport Systems' temperature-controlled supply chain solutions, including biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling The Outcome™️ for patients around the world. Learn More. 
|
|
By Annalee Armstrong A doomed merger sent Infinity pharma filing for bankruptcy last year. Now, the other half of that ill-fated deal is facing its end as well. |
Sponsored by InMed Pharmaceuticals InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease |
By James Waldron Having given up on its liver disease ambitions due to a lack of funds, Hepion Pharmaceuticals has decided that its best option is to merge into Israeli biotech Pharma Two B. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Nick Paul Taylor Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent and is delaying the use of Regeneron and Sanofi’s blockbuster. |
By Fraiser Kansteiner Agilent has revealed that it’s signed a definitive agreement to acquire Biovectra for $925 million through a mix of cash and debt financing. The deal is expected to close this year. |
By Heather Landi,Susan Kreimer,Annie Burky We are honoring leaders who have made a measurable impact on healthcare in the past year and have a demonstrated track record in paving the way forward for others. These leaders have shown examples of innovation, passion and ingenuity. |
By Conor Hale As Intuitive Surgical continues to roll out its latest da Vinci robot, following its launch in March, the company warned that supplies may be tight for the next 12 months. |
Fierce podcasts Don’t miss an episode |
| In February, Novo Holdings announced a $16.5 billion deal to acquire Catalent, and this week on "The Top Line," we explore the current state and implications of the proposed buyout. |
|
|---|
|
|
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
